Cargando…
12 Months Persistent Immunogenicity after Hepatitis B Vaccination in Patients with Type 2 Diabetes and Immunogenicity of Revaccination in Non-Responders: An Open-Label Randomized Controlled Trial
Background: In initial studies, the immunogenicity and safety of hepatitis B vaccines in patients with diabetes has been assessed in China. Methods: In six township health centers in Gansu Province, 232 diabetic patients and 77 healthy people were allocated to receive two 3-dose hepatitis B vaccines...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8705985/ https://www.ncbi.nlm.nih.gov/pubmed/34960153 http://dx.doi.org/10.3390/vaccines9121407 |
_version_ | 1784622081655177216 |
---|---|
author | Han, Bingfeng Liu, Wu Du, Juan Liu, Hanyu Zhao, Tianshuo Yang, Shubo Wang, Shuai Zhang, Sihui Liu, Bei Liu, Yaqiong Cui, Fuqiang |
author_facet | Han, Bingfeng Liu, Wu Du, Juan Liu, Hanyu Zhao, Tianshuo Yang, Shubo Wang, Shuai Zhang, Sihui Liu, Bei Liu, Yaqiong Cui, Fuqiang |
author_sort | Han, Bingfeng |
collection | PubMed |
description | Background: In initial studies, the immunogenicity and safety of hepatitis B vaccines in patients with diabetes has been assessed in China. Methods: In six township health centers in Gansu Province, 232 diabetic patients and 77 healthy people were allocated to receive two 3-dose hepatitis B vaccines (Group D20SC 0-1-6; Group D20CHO 0-1-6; Group ND20SC 0-1-6). Participants were followed up at 12 months after being fully vaccinated. One dose of the vaccine was randomly administered to non-responders. Chi-square test was used to compare the differences in response rate between two groups. Results: The anti-HBs response rates of three groups decreased from 84.1%, 89.1% and 88.3% at one month to 64.6%, 79.8% and 71.4% at twelve months. There was no statistical difference in the immune response rates between Group D20SC 0-1-6 and Group ND20SC 0-1-6; however, that of Group D20CHO 0-1-6 was higher than that of Group D20SC 0-1-6. After revaccination, the geometric mean concentrations were 491.7 mIU/mL and 29.7 mIU/mL after using vaccines containing 60 μg and 20 μg HBsAg. Conclusions: At 12 months, immune response in diabetic patients were not significantly different from that in healthy people. Revaccination with one dose of hepatitis B vaccine containing 60 μg HBsAg for non-responders was more satisfactory. |
format | Online Article Text |
id | pubmed-8705985 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-87059852021-12-25 12 Months Persistent Immunogenicity after Hepatitis B Vaccination in Patients with Type 2 Diabetes and Immunogenicity of Revaccination in Non-Responders: An Open-Label Randomized Controlled Trial Han, Bingfeng Liu, Wu Du, Juan Liu, Hanyu Zhao, Tianshuo Yang, Shubo Wang, Shuai Zhang, Sihui Liu, Bei Liu, Yaqiong Cui, Fuqiang Vaccines (Basel) Article Background: In initial studies, the immunogenicity and safety of hepatitis B vaccines in patients with diabetes has been assessed in China. Methods: In six township health centers in Gansu Province, 232 diabetic patients and 77 healthy people were allocated to receive two 3-dose hepatitis B vaccines (Group D20SC 0-1-6; Group D20CHO 0-1-6; Group ND20SC 0-1-6). Participants were followed up at 12 months after being fully vaccinated. One dose of the vaccine was randomly administered to non-responders. Chi-square test was used to compare the differences in response rate between two groups. Results: The anti-HBs response rates of three groups decreased from 84.1%, 89.1% and 88.3% at one month to 64.6%, 79.8% and 71.4% at twelve months. There was no statistical difference in the immune response rates between Group D20SC 0-1-6 and Group ND20SC 0-1-6; however, that of Group D20CHO 0-1-6 was higher than that of Group D20SC 0-1-6. After revaccination, the geometric mean concentrations were 491.7 mIU/mL and 29.7 mIU/mL after using vaccines containing 60 μg and 20 μg HBsAg. Conclusions: At 12 months, immune response in diabetic patients were not significantly different from that in healthy people. Revaccination with one dose of hepatitis B vaccine containing 60 μg HBsAg for non-responders was more satisfactory. MDPI 2021-11-29 /pmc/articles/PMC8705985/ /pubmed/34960153 http://dx.doi.org/10.3390/vaccines9121407 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Han, Bingfeng Liu, Wu Du, Juan Liu, Hanyu Zhao, Tianshuo Yang, Shubo Wang, Shuai Zhang, Sihui Liu, Bei Liu, Yaqiong Cui, Fuqiang 12 Months Persistent Immunogenicity after Hepatitis B Vaccination in Patients with Type 2 Diabetes and Immunogenicity of Revaccination in Non-Responders: An Open-Label Randomized Controlled Trial |
title | 12 Months Persistent Immunogenicity after Hepatitis B Vaccination in Patients with Type 2 Diabetes and Immunogenicity of Revaccination in Non-Responders: An Open-Label Randomized Controlled Trial |
title_full | 12 Months Persistent Immunogenicity after Hepatitis B Vaccination in Patients with Type 2 Diabetes and Immunogenicity of Revaccination in Non-Responders: An Open-Label Randomized Controlled Trial |
title_fullStr | 12 Months Persistent Immunogenicity after Hepatitis B Vaccination in Patients with Type 2 Diabetes and Immunogenicity of Revaccination in Non-Responders: An Open-Label Randomized Controlled Trial |
title_full_unstemmed | 12 Months Persistent Immunogenicity after Hepatitis B Vaccination in Patients with Type 2 Diabetes and Immunogenicity of Revaccination in Non-Responders: An Open-Label Randomized Controlled Trial |
title_short | 12 Months Persistent Immunogenicity after Hepatitis B Vaccination in Patients with Type 2 Diabetes and Immunogenicity of Revaccination in Non-Responders: An Open-Label Randomized Controlled Trial |
title_sort | 12 months persistent immunogenicity after hepatitis b vaccination in patients with type 2 diabetes and immunogenicity of revaccination in non-responders: an open-label randomized controlled trial |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8705985/ https://www.ncbi.nlm.nih.gov/pubmed/34960153 http://dx.doi.org/10.3390/vaccines9121407 |
work_keys_str_mv | AT hanbingfeng 12monthspersistentimmunogenicityafterhepatitisbvaccinationinpatientswithtype2diabetesandimmunogenicityofrevaccinationinnonrespondersanopenlabelrandomizedcontrolledtrial AT liuwu 12monthspersistentimmunogenicityafterhepatitisbvaccinationinpatientswithtype2diabetesandimmunogenicityofrevaccinationinnonrespondersanopenlabelrandomizedcontrolledtrial AT dujuan 12monthspersistentimmunogenicityafterhepatitisbvaccinationinpatientswithtype2diabetesandimmunogenicityofrevaccinationinnonrespondersanopenlabelrandomizedcontrolledtrial AT liuhanyu 12monthspersistentimmunogenicityafterhepatitisbvaccinationinpatientswithtype2diabetesandimmunogenicityofrevaccinationinnonrespondersanopenlabelrandomizedcontrolledtrial AT zhaotianshuo 12monthspersistentimmunogenicityafterhepatitisbvaccinationinpatientswithtype2diabetesandimmunogenicityofrevaccinationinnonrespondersanopenlabelrandomizedcontrolledtrial AT yangshubo 12monthspersistentimmunogenicityafterhepatitisbvaccinationinpatientswithtype2diabetesandimmunogenicityofrevaccinationinnonrespondersanopenlabelrandomizedcontrolledtrial AT wangshuai 12monthspersistentimmunogenicityafterhepatitisbvaccinationinpatientswithtype2diabetesandimmunogenicityofrevaccinationinnonrespondersanopenlabelrandomizedcontrolledtrial AT zhangsihui 12monthspersistentimmunogenicityafterhepatitisbvaccinationinpatientswithtype2diabetesandimmunogenicityofrevaccinationinnonrespondersanopenlabelrandomizedcontrolledtrial AT liubei 12monthspersistentimmunogenicityafterhepatitisbvaccinationinpatientswithtype2diabetesandimmunogenicityofrevaccinationinnonrespondersanopenlabelrandomizedcontrolledtrial AT liuyaqiong 12monthspersistentimmunogenicityafterhepatitisbvaccinationinpatientswithtype2diabetesandimmunogenicityofrevaccinationinnonrespondersanopenlabelrandomizedcontrolledtrial AT cuifuqiang 12monthspersistentimmunogenicityafterhepatitisbvaccinationinpatientswithtype2diabetesandimmunogenicityofrevaccinationinnonrespondersanopenlabelrandomizedcontrolledtrial |